Published in Hepatitis Weekly, July 30th, 2007
"The purpose of this study was to assess the risk of developing, thyroid disease with pegylated IFN (pIFN) versus regular IFN (rIFN) therapy (in combination with RBV). We also pooled our results with previous studies in a meta-analysis. An observational study was made retrospectively of 24 patients who underwent a combination of rIFN and RBV therapy for,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.